These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 12082199)
21. Abciximab readministration: results of the ReoPro Readministration Registry. Tcheng JE; Kereiakes DJ; Lincoff AM; George BS; Kleiman NS; Sane DC; Cines DB; Jordan RE; Mascelli MA; Langrall MA; Damaraju L; Schantz A; Effron MB; Braden GA Circulation; 2001 Aug; 104(8):870-5. PubMed ID: 11514371 [TBL] [Abstract][Full Text] [Related]
22. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463 [TBL] [Abstract][Full Text] [Related]
23. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. EPILOG Investigators N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212 [TBL] [Abstract][Full Text] [Related]
24. Abciximab: a review and update for clinicians. Mazzaferri EL; Young JJ Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):609-18. PubMed ID: 18510478 [TBL] [Abstract][Full Text] [Related]
25. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637 [TBL] [Abstract][Full Text] [Related]
26. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970 [TBL] [Abstract][Full Text] [Related]
27. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
29. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Kereiakes DJ Am Heart J; 1999 Jul; 138(1 Pt 2):S39-46. PubMed ID: 10385790 [TBL] [Abstract][Full Text] [Related]
30. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331 [TBL] [Abstract][Full Text] [Related]
31. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding. Aylward P Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944 [No Abstract] [Full Text] [Related]
32. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction. Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517 [TBL] [Abstract][Full Text] [Related]
33. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Casterella PJ; Revenaugh JR; Burke JL; Pearson RR; Bair TL; May HT; Horne B; Anderson JL; Muhlestein JB J Invasive Cardiol; 2008 Mar; 20(3):94-8. PubMed ID: 18316822 [TBL] [Abstract][Full Text] [Related]
34. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733 [TBL] [Abstract][Full Text] [Related]
35. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156 [TBL] [Abstract][Full Text] [Related]